Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04032860
PHASE4

RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection

Sponsor: West China Hospital

View on ClinicalTrials.gov

Summary

In Asia, hepatocellular carcinoma (HCC) commonly occurred in the underlying hepatitis B virus (HBV)-related liver disease.Curative therapies could improve the prognosis of HCC patients. However, tumor recurrence after curative therapy remains high with a 5-year recurrence rate \>70%.The risk for HCC development is increased for patient with HBV infection,but there was no consensus about which kind of oral antiviral treatment was the best option in the prevention of HBV related HCC recurrence after curative treatment.Therefore, we conducted this study to investigate the different effects of nucleotides(TDF) and nucleosides(ETV) on the prognosis of HBV-related HCC after curative resection.

Official title: The Different Effects of Nucleotide and Nucleoside Analogues on the Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients After Curative Resection:a Randomized Controlled Trial

Key Details

Gender

All

Age Range

18 Years - 69 Years

Study Type

INTERVENTIONAL

Enrollment

104

Start Date

2017-07-01

Completion Date

2026-07-01

Last Updated

2022-05-25

Healthy Volunteers

No

Interventions

DRUG

Tenofovir Disoproxil

patients with HBV-HCC would take TDF as antiviral therapy before curative treatment to see the prognosis after surgery

DRUG

Entecavir

patients with HBV-HCC would take ETV as antiviral therapy before curative treatment to see the prognosis after surgery

Locations (1)

West China Hospital, Sichuan University

Chengdu, Sichuan, China